Form 4: Adaptive Biotechnologies CPO Sells Shares

Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised options and sold 3,125 shares of common stock for a profit, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp., executed transactions involving the company's common stock on January 2, 2026.
• Lo acquired 3,125 shares of common stock through the exercise of stock options at a price of $3.99 per share.
• Concurrently, Lo sold 3,125 shares of common stock at a weighted-average price of $16.08 per share, with individual sales prices ranging from $15.77 to $16.40.
• These transactions were conducted under a Rule 10b5-1 trading plan that was adopted by Lo on September 15, 2025.
• Following these transactions, Lo directly beneficially owns 315,978 shares of common stock and indirectly owns 2,500 shares through a spouse.
• Lo also directly beneficially owns 104,856 stock options with an exercise price of $3.99, which began vesting on March 4, 2025, with 1/4 of shares vesting then, and 1/48 of shares vesting at the end of each full month of continuous service thereafter.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a pre-arranged plan, indicating no new material information. The insider realized a profit, which is positive for them. For the company, it's a standard disclosure.

Positives

• The Chief People Officer realized a significant profit by exercising options at $3.99 and selling shares at an average of $16.08.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned activity rather than a reaction to new, non-public information.

Negatives

• Insider selling, even when conducted under a 10b5-1 plan, can sometimes be perceived negatively by investors as it reduces management's direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Francis Lo's spouse, You Jin Lee, indirectly owns 2,500 shares of Common Stock.

Stakeholder Impact

• Shareholders may view the insider sale as a minor negative, although this is mitigated by the pre-arranged 10b5-1 plan. The total number of shares sold is relatively small compared to the company's overall outstanding shares.
• Francis Lo, as a member of management, successfully monetized a portion of his equity compensation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. Such transactions are generally not indicative of new material information about the company's performance or prospects. While insider selling can sometimes be a minor negative signal, the pre-planned nature mitigates this concern. Therefore, this specific filing alone does not provide sufficient new information to warrant a change in investment recommendation; a "hold" stance is appropriate, pending further company-specific or market-wide developments.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Francis Lo, Chief People Officer, 10b5-1 Plan